CHICAGO — In patients with stage IVB anaplastic thyroid cancer, the inclusion of adjuvant pembrolizumab to conventional multimodal therapy shows significant benefits in reducing the recurrence ...

In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received pembrolizumab developed immune-related adverse events — findings that ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Dr. Shannon Westin (Host), Dr. Brian Slomovitz (Guest) Dr. Shannon Westin and her guest, Dr. Brian Slomovitz discuss the article “Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without ...

At a median follow-up of 29.9 months (range, 12.8-43.0), significant differences in overall survival (OS) were observed between the pembrolizumab plus chemoradiotherapy group and the chemoradiotherapy ...

It’s debuting today with a collection of magnetic peripherals called Flow that’s centered around a wireless split keyboard, all designed to make it easier to find your perfect ergonomic layout ...

Design We correlated the prognostic outcomes of HCC patients from a pembrolizumab trial (NCT03419481) with tumourous cell expressions of all HDAC isoforms by single-cell RNA sequencing. We ...

As a second-line treatment, the patient received pembrolizumab, an ICI that targets programmed death-1 (PD-1), a checkpoint located on immune cells. After three treatment cycles, the patient ...

Currently, several combination regimens have been approved, including atezolizumab plus bevacizumab, pembrolizumab plus lenvatinib, camrelizumab plus apatinib, and sintilimab plus bevacizumab ...

They then got an intensification cycle of chemotherapy for [central nervous system] prophylaxis, and then we assessed their measurable residual disease, or MRD status, by flow cytometry. If they were ...